Related Experiment Video

Updated: May 10, 2026

Manufacture and Drug Delivery Applications of Silk Nanoparticles
09:03

Manufacture and Drug Delivery Applications of Silk Nanoparticles

Published on: October 8, 2016

16.8K

Bankruptcy filing worries developers of nanoparticle cancer drugs

Heidi Ledford

    Nature
    |May 20, 2016
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines
    07:59

    A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines

    Published on: March 4, 2017

    9.5K
    Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
    09:34

    Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

    Published on: February 9, 2019

    9.5K

    Related Experiment Videos

    Last Updated: May 10, 2026

    Manufacture and Drug Delivery Applications of Silk Nanoparticles
    09:03

    Manufacture and Drug Delivery Applications of Silk Nanoparticles

    Published on: October 8, 2016

    16.8K
    A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines
    07:59

    A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines

    Published on: March 4, 2017

    9.5K
    Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
    09:34

    Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

    Published on: February 9, 2019

    9.5K

    Related Concept Videos

    Preclinical Development: Overview01:28

    Preclinical Development: Overview

    Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
    Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

    Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

    Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...

    Articles linked to this work by shared authors, journal, and citation graph.

    Population-scale immune multiome atlas reveals regulatory disease mechanisms.

    Nature·2026

    A TBK1/ULK1 signalling axis couples lysosomal stress to TFEB activation.

    Nature·2026

    Type 2 immune history trains lung macrophages for viral disease tolerance.

    Nature·2026

    Sugar-rich foods exacerbate antibiotic-induced microbiome disruption.

    Nature·2026

    Osteoclasts intercept meningeal lymphatic paths for dural metastasis.

    Nature·2026

    Self-aligned optical microcomb emerging between octave-separated lasers.

    Nature·2026

    Sacituzumab govitecan in metastatic breast cancer: a systematic review and meta-analysis of its clinical benefit and safety.

    Frontiers in medicine·2026

    Nerandomilast is Associated With Altered Alveolar Epithelial Cell State Dynamics While Attenuating Fibrotic Remodeling in Pulmonary Fibrosis.

    Genes to cells : devoted to molecular & cellular mechanisms·2026

    Inhibition of the NR4A1-mediated cell cycle checkpoint enhances hyperplastic adipogenesis and glucose homeostasis in obesity.

    British journal of pharmacology·2026

    Inhibition of ROR1 signaling with zilovertamab plus ibrutinib in chronic lymphocytic leukemia: safety, mechanistic insights, and an exploratory signal in del(17p) disease.

    Leukemia·2026

    Integrated morphological and transcriptomic analysis of bone disorders in aldosterone-salt hypertension.

    Hypertension research : official journal of the Japanese Society of Hypertension·2026

    TFAM loss drives oxaliplatin resistance by linking mtDNA release to STING-TBK1-mediated lysophagy.

    Oncogene·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us